Investment Pitches

Pitch Summary:
Chemed (CHE), engages in the provision of healthcare and maintenance services operating through two segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of health care providers, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The stock declined due to concerns surrounding the potential Medicare cap limits proposed in current legislation for its VITAS segment alongside weaker residential demand for its plumbing services segment. We continue to maintain our position, as we believe the slowing demand in the Roto-Rooter segment is transitory and the secular demand for hospice care remains strong.

BSD Analysis:
Chemed is a strange beast: part hospice powerhouse (VITAS), part plumbing and restoration royalty (Roto-Rooter) — and both are quietly excellent businesses. Hospice demand grows as the population ages and care shifts from hospitals to lower-cost settings, and VITAS has scale and clinical depth that smaller operators lack. Roto-Rooter, meanwhile, is an all-weather cash machine — when something breaks, people don’t “wait for macro to improve,” they just pay. The portfolio looks odd, but the cash-flow profile is outstanding: recurring, diversified, and recession-resistant. Management has historically been disciplined in capital allocation and buybacks. Chemed is the kind of name you own for a decade and forget about — until you notice how much it compounded.

Pitch Summary:
Founded in 2009 and headquartered in San Francisco, California, Uber is a global technology platform that facilitates the movement of people, goods and services across a wide range of markets. What began as a simple ride-hailing app has evolved into a multi-segment leader operating in more than 70 countries, connecting millions of consumers, drivers, couriers and merchants worldwide. Uber’s operations are organized into three primary business segments: Mobility, which includes ridesharing, car rentals and other personal transportation services (~45% of revenue); Delivery, which spans food, grocery, convenience and retail delivery through the Uber Eats platform (~50%); and Freight, its digital brokerage and logistics arm (~5%). These segments are built on a shared platform supported by real-time matching technology, global app penetration, strong network effects and one of the most recognized consumer brands globally—reflected in the familiar phrase, “I’ll call an Uber.” Some of the quality characteristics we have identified for Uber include: global scale and platform efficiency; an integrated, cross-segment ecosystem—where offerings like Uber One memberships drive customer activity and loyalty; and market leadership across core categories, including approximately 70% market share in U.S. ridesharing, a strong #2 position in U.S. delivery, and leading positions in key international delivery markets. Uber has scaled to sustainably FREE cash flow with continued progress on margin expansion driven by scale and disciplined cost control. Catalysts we have identified include: increased profitability as cross-promotion deepens user engagement; partnerships with taxi fleets, travel platforms and autonomous vehicle companies; and continued expansion in non-urban markets with features like Uber Reserve.

BSD Analysis:
Uber finally did the unthinkable: it became a real business with real free cash flow instead of a perpetual “growth at any cost” experiment. Mobility is humming, delivery is sticky post-COVID, and the company’s advertising and membership layers are starting to matter. Network density gives Uber a moat in both driver supply and customer convenience that would cost competitors billions to replicate. Regulatory headaches never fully go away, but Uber has proven it can adapt and still expand margins. With fixed costs leveraged and capital discipline now embedded, incremental revenue drops through at a rate early investors only dreamed about. This is a dominant urban-transport infrastructure play, not just an app on your phone.

Pitch Summary:
Alcon, a global leader in eye care, was one of the largest detractors during the quarter. Aside from its earnings report, there was little material news, and we did not view anything in the report as affecting the company’s long-term fundamentals. While quarterly updates can influence sentiment, our focus remains on the strength and quality of the business. Alcon operates in a resilient, oligopolistic industry with high barriers to entry and recurring revenue streams tied to its large installed base of cataract surgery systems. It also continues to innovate across product categories, including its premium intraocular lens portfolio (e.g., PanOptix, Vivity), ultra-premium daily contact lenses (e.g., Dailies Total1) and over-the-counter products, such as Systane for dry eyes. Since its spinoff from Novartis in 2019, the company has also demonstrated greater agility in R&D, commercial execution and capital allocation—catalysts we previously identified. More broadly, we believe Alcon’s ability to strengthen its partnerships with eye care professionals and broaden access to underutilized premium technologies makes the company uniquely positioned to benefit from an aging population, increased access to eye care in emerging markets, and rising awareness and diagnosis of chronic dry eye conditions.

BSD Analysis:
Alcon is the quiet medtech powerhouse riding one of the most reliable demographic megatrends on the planet: aging eyes. Cataract procedures keep growing, premium intraocular lenses are taking share, and Alcon owns the surgical suite with an installed base competitors can’t realistically displace. Its vision-care segment adds a sticky, high-margin consumer layer that hums regardless of macro noise — people don’t stop buying contacts and eye drops in a recession. Margins continue expanding as post-spin execution pays off, the product pipeline is better than investors give it credit for, and Alcon’s global footprint gives it leverage in both emerging and developed markets. The market still prices this like a slow, steady medtech name, but the truth is Alcon has multiple structural tailwinds, relentless repeat revenue, and a surgical franchise with decades of runway. This is a compounding engine hiding inside a conservative multiple.

Pitch Summary:
Amgen, the biopharmaceutical company, was one of the largest detractors for the quarter. While the company’s branded drugs continued to advance (a previously identified catalyst), with cholesterol medicine Repatha, osteoporosis treatment Evenity and bone-strengthening drug Prolia all growing sales in the double digits, concerns surrounding potential tariff impacts, tax reform and pressure on drug prices weighed on shares. We believe it is too early to assess the full impact of these macro uncertainties and are confident in Amgen’s demonstrated ability to adapt through evolving policy and pricing dynamics. The company reaffirmed its long-term commitment to domestic manufacturing and innovation through its upcoming $2 billion expansions in Ohio and North Carolina, building on more than $5 billion in U.S. operational investments since 2017. Furthermore, Amgen continued to advance its robust pipeline, as its 1L bemarituzumab (bema) phase 3 trial for gastric cancer met its primary endpoint, and MariTide, the company’s weight-loss drug, demonstrated strong efficacy in phase 1 and 2 trials. MariTide, which could offer more convenient monthly dosing compared to daily or weekly regimens, showed promising early results, though tolerability will be an important focus heading into phase 3. Management noted that modified dose ramp-up strategies may help mitigate these effects. Despite near-term pressures, we remain encouraged by Amgen’s continued market share gains across key therapies and the potential to enhance the company’s competitiveness and resilience in a dynamic healthcare landscape.

BSD Analysis:
Amgen is the large-cap biotech that morphed from a couple of blockbuster cash cows into a diversified, innovation-forward platform with genuine pipeline depth. Legacy drugs still throw off tons of cash, but newer assets in oncology, inflammation, and rare disease are increasingly doing the heavy lifting. The Horizon acquisition beefed up the rare disease portfolio and expanded Amgen’s specialty footprint. Biosimilars add an interesting, steady growth leg most big pharmas don’t fully enjoy. The balance sheet can handle deals, the dividend is solid, and management has been more disciplined than peers on both price and risk. You’re basically getting a pharma-biotech hybrid that still isn’t priced like a top-tier pipeline story.

Pitch Summary:
Microchip Technology, the microcontroller (MCU) and analog semiconductor producer, was a top contributor for the quarter. After several quarters of underperformance driven by prolonged customer destocking, the company’s fundamentals began to improve meaningfully, as returning CEO Steve Sanghi’s turnaround plan is underway. Bookings showed signs of stabilization, supported by more balanced inventories across customers and distribution channels, as well as indications of recovering end-market demand. Operational execution also improved under the renewed leadership, with early benefits emerging from cost-saving initiatives—such as the closure of its Arizona wafer fabrication facility—and tighter inventory management. Microchip’s long-standing customer relationships and commitment to extended product lifecycles continue to support recurring revenue and reduce design-in risk. Combined with its consistent record of strong FREE cash flow generation and shareholder returns, this disciplined approach reinforces our conviction in the company’s ability to manage through industry cycles. Longer term, we believe Microchip remains well-positioned to gain share in 16- and 32-bit MCUs and areas including IoT, 5G infrastructure, autonomous vehicles and data centers.

BSD Analysis:
Microchip is the cash-generating microcontroller and analog beast riding the slow, grinding digitization of everything — autos, industry, aerospace, and IoT. Its end markets aren’t flashy, but they’re sticky and product lifecycles are measured in decades. That means design wins turn into long-lived, high-margin annuities. The recent downturn and inventory correction are cyclical noise in a structurally growing content story. Microchip’s capital allocation — de-lever, dividends, buybacks — is shareholder-friendly without starving R&D. When the cycle turns, the operating leverage here is bigger than the sleepy ticker suggests.

Pitch Summary:
Microsoft, the global leader in software and enterprise services, was the top contributor for the quarter. The company delivered a strong quarterly update, with Azure revenue growing 35%—well ahead of expectations—driven by improved execution in core cloud services and sustained AI-related demand. Importantly, strength extended beyond AI, with renewed momentum in traditional enterprise cloud workloads, such as data platforms, infrastructure hosting and developer services. Profitability also impressed, with operating margins expanding to 46% supported by disciplined cost control. While near-term results were strong, our conviction remains grounded on Microsoft’s enduring advantages: dominant positions in mission-critical software, high recurring revenue driven by a deep subscriber base, and the ability to reinvest at scale. One example is GitHub Copilot—a generative AI tool that helps developers write, review and debug code—which now has over 15 million users and is seeing increasing enterprise adoption. With widespread use of offerings like Copilot, Teams and LinkedIn, and underpinned by robust FREE cash flow supporting continued innovation, we believe Microsoft remains exceptionally well-positioned to compound value across cloud, productivity and AI-enabled workflows over the long term.

BSD Analysis:
Microsoft has essentially put a tollbooth on enterprise AI adoption: if you’re a corporate CIO, the default answer is “we’ll just do it inside Microsoft.” Azure, Copilot, GitHub, Security — every layer monetizes AI in a way that compounds across the stack. The company’s distribution advantage is absurd: it can light up new AI features across millions of users with one SKU decision. Meanwhile, core businesses like Office and Windows keep generating monster free cash flow to fund the AI arms race. The balance sheet is pristine, buybacks are relentless, and switching costs are effectively career risk for IT leaders. Microsoft doesn’t need to win every AI narrative battle — it’s already won the seat at the enterprise table.

Pitch Summary:
Safran, the French aerospace propulsion and equipment manufacturer, was a top contributor during the quarter. The company continues to demonstrate high-quality characteristics—namely durable aftermarket revenue, strong pricing power and long-standing customer relationships across its propulsion, avionics and interiors franchises. Record 2024 results carried into 2025, supported by strong air traffic recovery, particularly in Asia, and increased aircraft utilization. As the dominant supplier of narrow-body aircraft engines (approximately 70% market share), Safran benefits from rising demand for required maintenance as airlines extend the lives of aging fleets. With roughly one-fifth of its revenues tied to defense, the company also stands to gain from rising European defense budgets, where policymakers are placing increased emphasis on sourcing from regional suppliers. We also continue to view the transition from the legacy CFM56 engine to the more fuel-efficient LEAP platform as a meaningful catalyst—especially given that a large portion of the installed LEAP fleet has yet to reach its first maintenance cycle, providing a long and visible runway (pardon the pun) of profit growth. Looking ahead, we believe Safran remains well-positioned to benefit from global fleet modernization and the industry’s pivot toward more efficient and sustainable aircraft platforms.

BSD Analysis:
Safran is one half of the duopoly that powers most of the world’s narrow-body fleet — CFM engines — and that alone gives it a multi-decade revenue stream. The post-COVID air traffic recovery, plus an aging fleet needing more efficient engines, gives Safran visibility that most industrials would kill for. Its aftermarket business is a high-margin machine as more engines need maintenance and overhauls. On top of that, Safran has serious exposure to avionics and defense, which add both resilience and upside as global budgets rise. Temporary supply-chain issues are noise compared to the structural air travel and defense tailwinds. This is a premium aerospace compounder still not fully priced like one.

Pitch Summary:
LVMH Moët Hennessy Louis Vuitton, the global leader in luxury goods, was one of the largest detractors for the quarter. While the luxury goods industry is experiencing a cyclical slowdown, we believe LVMH’s fundamentals remain sound. The company continues to demonstrate long-term brand stewardship, integrating global maisons at scale while preserving their creative autonomy. Although Dior—responsible for 16% of group profits—underperformed in 2024 due to pricing fatigue and softer product innovation, LVMH responded decisively by naming Jonathan Anderson, the designer credited with revitalizing Loewe, as Dior’s new creative director. Despite mixed macro demand, other brands such as Sephora, Loewe and Tiffany reported strong growth, underscoring the breadth and durability of the group’s diversified portfolio. Operating margins declined modestly, as management chose to preserve brand equity and marketing investment rather than cut costs into weakness. Free cash flow improved year-over-year, and the company ended 2024 with €10 billion in cash, highlighting its strong and flexible balance sheet. As Asian demand stabilizes and innovation pipelines refresh, we believe LVMH’s scale, vertical integration and revitalized creative leadership will drive its success in the long run.

BSD Analysis:
LVMH is the final boss of global luxury — portfolios of brands so powerful they bend consumer behavior and pricing to their will. Short-term noise around China or aspirational shoppers doesn’t change the long-term math: ultra-high-net-worth consumers are expanding, and LVMH owns their closets, cellars, and suitcases. Vertical integration, tight control of distribution, and ruthless brand management keep competitors permanently on the back foot. Its balance sheet is a fortress, cash generation is enormous, and management has a long track record of buying great assets and making them better. This isn’t a fashion stock; it’s a luxury monopoly with multi-decade duration. The market regularly forgets that — and then remembers in a hurry.

Pitch Summary:
Alcon, a global leader in eye care, was one of the largest detractors during the quarter. Aside from its earnings report, there was little material news, and we did not view anything in the report as affecting the company’s long-term fundamentals. While quarterly updates can influence sentiment, our focus remains on the strength and quality of the business. Alcon operates in a resilient, oligopolistic industry with high barriers to entry and recurring revenue streams tied to its large installed base of cataract surgery systems. It also continues to innovate across product categories, including its premium intraocular lens portfolio (e.g., PanOptix, Vivity), ultra-premium daily contact lenses (e.g., Dailies Total1) and over-the-counter products, such as Systane for dry eyes. Since its spinoff from Novartis in 2019, the company has also demonstrated greater agility in R&D, commercial execution and capital allocation—catalysts we previously identified. More broadly, we believe Alcon’s ability to strengthen its partnerships with eye care professionals and broaden access to underutilized premium technologies makes the company uniquely positioned to benefit from an aging population, increased access to eye care in emerging markets, and rising awareness and diagnosis of chronic dry eye conditions.

BSD Analysis:
Alcon is a pure-play on aging demographics and rising visual needs — surgical ophthalmology and vision care with real clinical and pricing moats. Cataract procedures, premium lenses, and advanced surgical equipment create a high-margin, tech-enabled business that looks more like medtech than commoditized devices. The consumables and equipment installed base create recurring revenue that hums along regardless of short-term macro noise. Contact lenses and eye drops add a steady consumer layer on top. Management has steadily expanded margins post spin-out and is reinvesting in innovation rather than financial engineering. This is a structurally growing, underappreciated franchise in a category where demand only moves one way: up.

Pitch Summary:
NeoGenomics remains the leading pure-play provider of specialty oncology lab testing services, serving hospitals, oncologists, and pathologists. We believe the company’s competitive advantage stems from its extensive testing menu, ability to serve as a comprehensive one-stop solution, strong commercial presence, trusted reputation among pathologists, and nationwide laboratory network. Shares detracted from performance after the company reported slightly weaker-than-expected revenues, although it exceeded consensus estimates for earnings before interest, taxes, depreciation, and amortization (EBITDA). Management noted that the revenue shortfall was primarily attributed to weakness in non-clinical segments, such as pharma services, reflecting broader cyclical pressures from reduced funding in the biopharma industry. Nevertheless, the company reaffirmed its full-year 2025 organic revenue guidance, while total revenue guidance was slightly increased to reflect a recent acquisition.

BSD Analysis:
NeoGenomics is emerging from years of operational chaos with a stronger diagnostic platform, tighter cost structure, and a clear path back to growth. Oncology testing volumes are rebounding, pharma services remain a high-margin engine, and new leadership is finally restoring discipline. The company sits at the intersection of precision medicine, companion diagnostics, and cancer screening — secular growth tailwinds the market is barely valuing. NeoGenomics isn’t fully out of the woods, but the turnaround is real and accelerating.

Pitch Summary:
RXO provides transportation services by matching customers with carriers, without owning many trucks itself. It operates mainly as a broker for two types of shipping: truckload (TL), where one customer's shipment fills an entire truck, and less-than-truckload (LTL), which combines smaller shipments from multiple customers into a single truck. The company also offers managed transportation services, freight forwarding, and last-mile delivery solutions. During the quarter, shares detracted from performance after the company reported weaker-than-expected revenues and earnings compared to analyst estimates. While its LTL segment performed well, the TL business experienced lower shipping volumes, despite higher revenue per shipment. While management indicated a weak April, they also highlighted encouraging progress in improving efficiency. In our view, these productivity improvements position RXO well to outperform the broader industry when market conditions improve.

BSD Analysis:
RXO is the asset-light logistics operator waiting for the freight cycle to flip — and when it does, margins recover fast. Its brokerage model gives it leverage without the balance sheet bloat of asset-heavy peers, and its tech stack is legitimately improving carrier and shipper matching. Market sentiment is awful for freight, which is exactly when RXO historically gains share. When volumes return, RXO’s operating leverage will look far better than the current multiple implies.

Pitch Summary:
Neogen develops, manufactures, and markets a diverse range of products dedicated to food and animal safety. Its Food Safety segment includes diagnostic test kits and related products used by food producers and processors to detect harmful or unintended substances in human food and animal feed. Its Animal Safety segment provides pharmaceuticals, vaccines, veterinary instruments, and genomic testing services. Shares detracted from performance during the quarter after the company reported fiscal third-quarter revenue and profitability below expectations. Additionally, management modestly lowered its full-year 2025 guidance, citing a weaker macroeconomic environment impacting food production volumes and the strategic decision to exit non-core areas within its animal genomics business.

BSD Analysis:
Neogen is riding a global wave of food safety tightening, pathogen testing expansion, and livestock biosecurity mandates. The acquisition of 3M’s food safety business solidified its dominance and unlocked synergies that are only now flowing through margins. Recurring consumables revenue keeps stacking, and Neogen’s global distribution footprint gives it a moat most diagnostic players envy. Investors treat this like a sleepy ag-testing name — but the regulatory tailwinds in food and animal safety are enormous.

Pitch Summary:
Acadia is a biopharmaceutical company that focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system (CNS) disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, and Daybue, designed for treating Rett Syndrome—a rare genetic disorder that affects brain development in children. Shares of Acadia contributed positively during the quarter after the company delivered better-than-expected fiscal first-quarter revenue driven by Nuplazid, which management highlighted is seeing the highest rate of new patient starts since 2020. Additionally, management reaffirmed its full-year 2025 revenue guidance, noting Daybue sales growth now appears more attainable following sequential patient growth after two quarters of stability, combined with consistent patient retention. Encouragingly, prescription growth from community-based healthcare providers—where most patients receive treatment—accelerated even prior to the completion of a roughly 30% salesforce expansion in the first quarter. With approximately 67% of Rett syndrome patients yet to try Daybue, we believe the product holds significant long-term growth potential.

BSD Analysis:
Acadia has quietly transformed from a one-drug story into a diversified CNS pipeline with serious commercial momentum. Nuplazid remains a meaningful cash generator, but the real growth engine is Daybue — one of the most significant rare-disease launches in years. Acadia’s pipeline expansion into neuropsychiatric and neurological disorders gives it multi-shot optionality. Margins are improving, commercial execution is strong, and regulatory risk is lower than most mid-cap biotechs. The market is still pricing Acadia like a single-asset company — that window is closing fast.

Pitch Summary:
Upstart Holdings, Inc. provides a cloud-based lending platform that uses artificial intelligence to help banks and lenders make better lending decisions. The company primarily offers personal loans but has also expanded into auto loans and other types of lending. Shares contributed positively during the quarter after the company reported strong fiscal-first quarter operating results, where management noted their credit quality remained stable, and newer products continued to gain traction. Auto loans and home equity lines of credit (HELOCs) both grew significantly, becoming a more meaningful part of the overall business. These new lending products involve collateral, which typically means the company earns slightly less per loan, but benefits from larger loan amounts and fewer defaults. As a result, management slightly raised its full-year guidance but remained cautious on their quarterly earnings call given ongoing economic uncertainty.

BSD Analysis:
Upstart went from fintech darling to market whipping boy — but the underwriting engine hasn’t gone away. As credit conditions stabilize, Upstart’s AI risk models get more useful, not less, and partner banks are slowly coming back online. Loan volumes are still depressed, but operating discipline has improved dramatically, and the company is no longer spending like a growth-obsessed startup. If funding markets reopen and banks start chasing yield again, Upstart has enormous torque. It’s still a high-risk name — but the asymmetry is back.

Pitch Summary:
Sterling Infrastructure, Inc. provides construction services across the United States for commercial and public sector customers. The company has three main business areas: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The E-Infrastructure Solutions segment is growing quickly and mainly involves projects such as data centers, e-commerce distribution facilities, manufacturing plants, warehouses, and power generation facilities. Shares contributed positively during the quarter after the company reported stronger-than-expected operating results, where the E-Infrastructure and Transportation segments performed better than expected, while results from Building Solutions were more mixed. Management noted that the E-Infrastructure Solutions segment is seeing continued growth in its backlog of future projects.

BSD Analysis:
Sterling is the kind of infrastructure contractor that investors ignore until the numbers smack them in the face. Its mix is shifting toward higher-margin e-infrastructure, data centers, and advanced manufacturing sites — exactly where the capex boom is hottest. Legacy construction provides stable cash, while transportation and heavy civil work fuel consistent backlog growth. Sterling’s discipline, conservative balance sheet, and execution record make it one of the cleanest ways to play America’s multi-year infrastructure supercycle. The stock is still priced like a mid-tier contractor — which it’s absolutely not.

Pitch Summary:
Globant is a global technology services company that helps businesses transform digitally by creating software solutions, leveraging AI, and providing cloud-based services. Its customers primarily include large companies across North America, Latin America, and Europe. Shares detracted from performance during the quarter after the company reported weaker-than-expected fiscal first-quarter results, as revenue growth missed analyst estimates. The revenue shortfall was mainly due to clients delaying discretionary IT and digital transformation projects amid macroeconomic uncertainty, particularly within its North American segment. Management highlighted that the slowdown in non-essential corporate spending—especially on projects unrelated to core operations or required digital upgrades—was the primary factor impacting new bookings and revenue growth.

BSD Analysis:
Globant is the IT consultancy that refuses to slow down — even when macro headwinds knock its peers into the fetal position. Its studio model gives it Swiss-army-knife flexibility across AI, cloud, games, fintech, and digital transformation. Enterprise demand is coming back, and Globant is winning disproportionately because its teams ship actual solutions, not buzzword decks. Margins held up through the slowdown, which tells you everything about its operational discipline. The market keeps mistaking temporary growth softness for structural weakness — it’s not. Once tech budgets reopen, Globant’s operating leverage will punch far above its weight.

Pitch Summary:
UnitedHealth Group integrates insurance benefits, primary care, pharmacy services, and data analytics, leveraging its scale to effectively address rising healthcare costs. Historically, the company has delivered strong double-digit earnings growth, driven by steady revenue expansion as more employers and payers adopt its solutions. However, this growth trajectory has recently been disrupted due to higher-than-anticipated utilization rates among Medicare Advantage (MA) members. Shares detracted from performance during the quarter after fiscal first-quarter earnings came in lower than expected, and management reduced full-year guidance, citing unexpected cost pressures from increased medical visits and specialist care early in the year. This was partly caused by higher-than-expected healthcare utilization from new MA members who had switched from competitors. In our view, profitability could improve next year as UnitedHealth and the broader MA industry implement higher pricing and government reimbursement rates adjust to reflect current utilization patterns.

BSD Analysis:
UnitedHealth is still the 800-pound gorilla of managed care — the only player with real scale advantages across data, claims processing, provider integration, and risk scoring. The Change Healthcare cyber mess was a black eye, but it didn’t dent the underlying economics: UNH controls the plumbing of U.S. healthcare, and everyone eLondon Stock Exchange pays rent. Optum remains a growth monster with margins most health providers would kill for, and its data flywheel keeps getting stronger as more care moves into value-based models. Medicare Advantage noise is temporary; UnitedHealth’s pricing power and actuarial precision aren’t. Cash flow remains enormous, the balance sheet is bulletproof, and UNH historically comes out of regulatory stress stronger, not weaker. This is still the healthcare stock everyone eLondon Stock Exchange quietly benchmarks against.

Pitch Summary:
Apple is a leading technology provider in telecommunications, computing, and services. Its proprietary iOS operating system represents a unique competitive strength, driving strong engagement with consumers and enterprises, and fostering purchases of high-margin services such as music, apps, and Apple Pay. During the quarter, shares detracted from performance after the company reported fiscal-second quarter results that broadly met analyst estimates but management lowered guidance citing tariff-related pressures on gross margins. While a potential foldable phone launch in 2026 may reinvigorate growth, the stock currently faces headwinds due to investor concerns about Apple’s relatively slower AI innovation compared to competitors. We remain constructive on Apple’s long-term prospects given its dominant platform and opportunities to expand into new verticals.

BSD Analysis:
Apple gets treated like a mature hardware company, but its ecosystem lock-in is one of the most powerful business models ever created. Services margins keep expanding, wearables remain sticky, and the iPhone cash machine continues to dominate globally. AI integration is slow but methodical — and when Apple rolls it out at scale, adoption will be instant. The installed base is massive, loyal, and practically immune to switching. Apple doesn’t need hypergrowth; it needs consistency, and it delivers every time. The company prints cash, buys back stock aggressively, and compounds value quietly while the market argues about innovation.

Pitch Summary:
Meta Platforms is the world’s largest social-media company, spanning Facebook, Instagram, WhatsApp and Messenger, and its Reality Labs arm pursues next-generation augmented- and virtual-reality hardware. Its Family of Apps averaged 3.4 billion daily active users in March 2025, highlighting the unrivalled scale that underpins its advertising franchise. The company’s AI-powered ad-delivery tools are driving higher pricing and better campaign performance, while new initiatives—such as the rollout of ads in WhatsApp—have the potential to unlock fresh revenue streams and are supported by a cash-rich balance-sheet that now includes a quarterly dividend. Shares rose during the quarter after fiscal first-quarter results came in better-than-expected due to strong revenue growth and operating margin expansion. Additionally, management guided fiscal second-quarter revenue above consensus and trimmed full-year expense guidance even as it lifted capital-expenditure plans to accelerate AI-infrastructure build-out.

BSD Analysis:
Meta is an advertising fortress running on AI-powered targeting that competitors still can’t match. Reels is monetizing fast, engagement is rising, and the company’s infrastructure investments put it ahead in AI capabilities. Despite Reality Labs burn, Meta can fund the metaverse experiment indefinitely with no strain. The market still undervalues the company’s unmatched ability to convert engagement into dollars. Meta is the most profitable attention engine on Earth — period.

Pitch Summary:
Microsoft is a beneficiary of corporate America’s transformative digitization. The company operates through three segments: Productivity and Business Processes (Office365, LinkedIn, and Dynamics), Intelligent Cloud (Server Products and Cloud Services, Azure, and Enterprise Services), and More Personal Computing (Windows, Devices, Gaming, and Search). We believe company fundamentals remain attractive because Azure’s scale—and the rollout of Copilot AI tools—deepens customer lock-in and expands high-margin subscription revenue. During the quarter, the company reported strong fiscal-fourth quarter earnings, driven by a reacceleration in Azure cloud sales that beat analyst estimates. Management also noted that AI-related sales growth exceeded expectations, accounting for 16% of Azure’s quarterly growth. While data center capacity eased, it did not eliminate AI-related supply constraints, and traditional enterprise cloud migrations re-accelerated, defusing worries that AI spending was crowding them out. Management also guided next quarter Azure sales growth higher than expected, citing sustained demand for both AI and core cloud services. With renewed enterprise cloud migrations easing fears that AI budgets were crowding out traditional workloads, the company’s share appreciated during the quarter, contributing to performance.

BSD Analysis:
Microsoft has built the most complete enterprise AI stack in existence — Azure for compute, Copilot for productivity, GitHub for developers, and Dynamics for workflows. Every large corporation is now tied into Microsoft’s AI strategy whether they realize it or not. Azure is winning share as AI workloads explode, and Copilot monetization has only just begun. Free cash flow is monstrous, margins are elite, and switching costs are near zero for Microsoft, and astronomical for customers. This is the most durable megacap in tech.